研究领域（方向）
1）肿瘤遗传与表观遗传学；2）肿瘤精准治疗；3）转化医学
个人及工作简历
祭美菊，女，研究员，博士生导师，2001年毕业于兰州大学生命科学学院，获得理学硕士。2001年9月进入东南大学生物医学工程学院攻读博士学位。2005年至2008年分别在东南大学及美国约翰·霍普金斯大学医学院从事博士后研究。2010年入职西安交通大学医学院第一附属医院，主要从事肿瘤遗传与表观遗传学研究，先后主持国家自然科学基金8项、中国博士后基金1项，共发表学术论文110余篇，其中以第一及通讯作者（含并列第一/通讯作者）发表SCI论文46篇，影响因子大于10的论文16篇。
学术及科研成果、专利、论文
代表论文（*通讯作者）
Pu J, Ma J, Liu Y, Cui R, Yao Y, Zhang G, Hou P, Liu X*, Yang Q*, Ji M*. Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma. Exp Mol Med. 2025. (IF: 17.5, Q1)
Dang H, Liu Y, Zhou Y, Sui M, Wang Y, Qiang W, Sui F, Zhang Y, Cao H, Wu X*, Ji M*, Hou P*. TET1 loss propels the development of hyperthyroidism by remodeling histone modifications of PAX8 promoter. Exp Mol Med. 2025 Oct;57(10):2376-2392. (IF: 17.5, Q1)
Zhang H, Zeng Z, Liu Y, Zheng W, Wang J, Yao Y, Wang Y, Ji M*, Hou P*. Thyrotropin exacerbates insulin resistance by triggering macrophage inflammation in subclinical hypothyroidism. Exp Mol Med. 2025. (IF: 17.5, Q1)
Liu Y, Yuan M, Xu X, Yang H, Yao Y, Hou P*, Yu W*, Ji M*. USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21. Int J Biol Sci. 2024 23;20(13):5223-5238. (IF: 11.7, Q1)
Sui F, Wang G, Liu J, Yuan M, Chen P, Yao Y, Zhang S, Ji M*, Hou P*. Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors. Cell Mol Life Sci. 2024 May 25;81(1):238. (IF: 6.5, Q1)
Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J, Cao H, Li Y, Ji M*, Hou P*. SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways. Exp Mol Med. 2023;55(8):1757-1769. (IF: 17.5, Q1)
Li X, Liu Y, Liu J, Qiang W, Ma J, Xie J, Chen P, Wang Y, Hou P*, Ji M*. STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells. Cell Death Dis. 2023 Jul 21;14(7):454. (IF: 12.2, Q1)
Dang H, Sui M, He Q, Xie J, Liu Y, Hou P, Ji M*. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways. Int J Biol Macromol. 2023 Sep 1;248:125867. (IF: 8.7, Q1)
Yang Q, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023;42(20):1634-8. (IF: 9.1, Q1)
He Q, Cao H, Zhao Y, Chen P, Wang N, Li W, Cui R, Hou P, Zhang X*, Ji M*. Dipeptidyl Peptidase-4 Stabilizes Integrin α4β1 Complex to Promote Thyroid Cancer Cell Metastasis by Activating Transforming Growth Factor-Beta Signaling Pathway. Thyroid. 2022 Nov; 32(11):1411-1422. (IF: 6.6, Q1)
Ma S, Wang N, Liu R, Zhang R, Dang H, Wang Y, Wang S, Zeng Z, Ji M*, Hou P*. ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase. J Exp Clin Cancer Res. 2021;40(1):387. (IF: 14.3, Q1)
Bai Z, Qu Y, Shi L, Li X, Yang Z, Ji M*, Hou P*. Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype. Cell Death Dis. 2021 Aug 3;12(8):765. (IF: 12.2, Q1)
Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, Lan X, Zhao Y, Qiang W, Ji M*, Hou P*. The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ. 2021;28(8):2450-2464. (IF: 13.6, Q1)
Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M*, Hou P*. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by improving hypoxic tumor microenvironment. J Nanobiotechnology. 2021;19(1):302. (IF: 15.0, Q1)
Li Y, Su X, Feng C, Liu S, Guan H, Sun Y, He N*, Ji M*, Hou P*. CYP2S1 is a synthetic lethal target in BRAF V600E-driven thyroid cancers. Signal Transduct Target Ther. 2020;5(1):191. ( IF: 81.2, Q1)
Li M, Ruan B, Wei J, Yang Q, Chen M, Ji M*, Hou P*. ACYP2 contributes to malignant progression of glioma through promoting Ca2+ efflux and subsequently activating c-Myc and STAT3 signals. J Exp Clin Cancer Res. 2020;39(1):106. (IF: 14.3, Q1)
Liu J, Yan J, Yan S, Wang Y, Zhang R, Hou P, He W*, Ji M*. Biomimetic and self-assembled nanoclusters targeting β-catenin for potent anticancer therapy and enhanced immunotherapy. Nano Lett. 2019;19(12):8708-8715. (IF: 9.1, Q1)
Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M*, Hou P*. Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 2019;9(15):4461-4473. (IF: 14.9, Q1)
Jiang W, Ji M*. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Semin Cancer Biol. 2019 Dec;59:3-22. (IF: 20.3, Q1)
Wei J, Yang Q, Shi J, Shi B, Ji M*, Hou P*. Increased expression of NAF1 contributes to malignant phenotypes of glioma cells through promoting protein synthesis and associates with poor patient survival. Oncogenesis. 2019 Apr 1;8(4):25. (IF: 6.0, Q1)
Wang N, Li Y, Wei J, Pu J, Liu R, Yang Q, Guan H, Shi B, Hou P*, Ji M*. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways. Thyroid. 2019 Mar;29(3):378-394. (IF: 6.6, Q1)
Li H, Tian Z, Qu Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis. Oncogene. 2019;38(3):345-359. (IF: 9.1, Q1)
Li Y, Yang Q, Guan H, Shi B, Ji M*, Hou P*. ZNF677 is a potent tumor suppressor in thyroid cancer through inhibiting Akt phosphorylation. Cancer Res. 2018;78(18):5216-5228. (IF: 22.6, Q1)
Shi J, Qu Y, Li X, Sui F, Yao D, Yang Q, Shi B, Ji M*, Hou P*. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis. 2016 Oct 27;7(10):e2442. (IF: 12.2, Q1)
Cui B, Yang Q, Guan H, Shi B, Hou P*, Ji M*. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. J Clin Endocrinol Metab. 2014 Jun;99(6):E962-70. (IF: 5.4, Q1)
Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M*. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci. 2012;13(4):4714-4726. (IF: 5.6, Q1)
Joseph B#, Ji M#, Liu D, Hou P, Xing M*. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007; 92:4766-70. (#并列第一作者；IF: 5.4, Q1)
Wang Y#, Ji M#, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J, Xing M*. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 2008; 15:183-90. (#并列第一作者；IF: 4.4, Q1)
Hou P#, Ji M#, Yang B, Chen Z, Qiu J, Shi X, Lu Z*. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 2006; 106:1602-9. (#并列第一作者；IF: 5.6, Q1)
联系方式
电子邮箱：mjji0409@163.com
联系电话：029-85324749 (O)
联系地址：交大一附院科教楼三楼
